# OnCo record epcore-nhl-1 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/epcore-nhl-1/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "epcore-nhl-1", "NCT03625037" ;
  schema:name "EPCORE NHL-1"@en ;
  schema:description "EPCORE NHL-1 was the pivotal single-arm study behind epcoritamab's approval; about half of complete responders are still in remission at three years."@en ;
  schema:url <https://onco.cc/trials/epcore-nhl-1/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03625037> ;
  onco:status "positive" ;
  onco:phase "1/2" ;
  schema:startDate "2018-06-26" ;
  onco:related <https://onco.cc/roadmaps/lymphoma-roadmap/>, <https://onco.cc/trials/polargo/>, <https://onco.cc/trials/starglo/> ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:drugs <https://onco.cc/drugs/epcoritamab/> ;
  onco:companies <https://onco.cc/companies/genmab/> ;
  onco:terms <https://onco.cc/terms/orr/>, <https://onco.cc/terms/crs/> ;
  onco:people <https://onco.cc/people/catherine-thieblemont/> .